Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
13.52
+0.64 (4.97%)
At close: Sep 4, 2025, 4:00 PM
13.50
-0.02 (-0.15%)
After-hours: Sep 4, 2025, 7:57 PM EDT

Company Description

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.

Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.

It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy.

It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain.

The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Mesoblast Limited
Mesoblast logo
CountryAustralia
Founded2004
IndustryBiotechnology
SectorHealthcare
Employees73
CEOSilviu Itescu

Contact Details

Address:
55 Collins Street, Level 38
Melbourne, VIC 3000
Australia
Phone61 3 9639 6036
Websitemesoblast.com

Stock Details

Ticker SymbolMESO
ExchangeNASDAQ
Fiscal YearJuly - June
Reporting CurrencyUSD
CIK Code0001345099
CUSIP Number590717104
ISIN NumberUS5907174016
SIC Code2836

Key Executives

NamePosition
Dr. Paul J. Simmons BSc, Ph.D.Scientific Advisor to the Chief Executive Officer
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board and Executive Director
Dr. Eric A. Rose M.D.Chief Medical Officer and Executive Director
Andrew Chaponnel B.Com.Interim Chief Finance Officer
Peter T. Howard B.Sc., L.L.B., LLB (Hons)General Counsel and Corporate Executive
Geraldine Storton B.Sc., M.B.A., MMSHead of Regulatory Affairs and Quality Management
Justin Horst B.S.Head of Manufacturing
Dr. Fiona See Ph.D.Senior Vice President and Head of Translational Research
Marcelo SantoroChief Commercial Officer
Niva Sivakumar B.Com., L.L.B.Joint Company Secretary

Latest SEC Filings

DateTypeTitle
Sep 4, 20256-KReport of foreign issuer
Aug 29, 20256-KReport of foreign issuer
Aug 29, 202520-FAnnual and transition report of foreign private issuers
Aug 27, 20256-KReport of foreign issuer
Jul 18, 20256-KReport of foreign issuer
Jul 15, 20256-KReport of foreign issuer
Jul 1, 20256-KReport of foreign issuer
Jun 12, 20256-KReport of foreign issuer
May 15, 20256-KReport of foreign issuer
Apr 30, 20256-KReport of foreign issuer